HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ZM 252868

Also Known As:

ZM-252868; ZM25268

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinazolines: 402
      - ZM 252868: 1

Related Diseases

1.	Ovarian Neoplasms (Ovarian Cancer) 03/01/1999 - "Inhibition of transforming growth factor alpha (TGF-alpha)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868."
2.	Carcinoma (Carcinomatosis) 03/01/1999 - "These data indicate that the EGF receptor-targeted TK inhibitor ZM 252868 can inhibit growth of ovarian carcinoma cells in vitro consistent with inhibition of tyrosine phosphorylation at the EGF receptor." 03/01/1999 - "The modulating effects of the epidermal growth factor (EGF) receptor-specific tyrosine kinase inhibitor ZM 252868 on cell growth and signalling have been evaluated in four ovarian carcinoma cell lines PE01, PE04, SKOV-3 and PE01CDDP. "

Related Drugs and Biologics

1.	ErbB Receptors (EGF Receptor)
2.	Transforming Growth Factor alpha (TGF-alpha)
3.	Tyrosine (L-Tyrosine)
4.	Epidermal Growth Factor (EGF)
5.	Tyrosine Kinase Inhibitors